European Journal of Pediatrics

, 169:245 | Cite as

Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation

  • Daniela Concolino
  • Gianluca Muzzi
  • Simona Sestito
  • Giovanna Vega
  • Giuseppe Bonapace
  • Pietro Strisciuglio
Short Report
  • 133 Downloads

Abstract

We assessed the efficacy and safety of recombinant human insulin-like growth factor 1 (IGF-1) therapy over a period of 7.5 years in a child with severe IGF-1 deficiency. Recombinant human IGF-1 was administered subcutaneously in doses between 40 and 80 μg/kg once daily. Height velocity increased from 2 cm/year on average at baseline to 7.9 cm/year during the first year of treatment. In the following years, growth velocity was less but satisfactory during treatment, but decreased when therapy was stopped.

Keywords

rhIGF-1 therapy IGF-1 gene mutation 

Notes

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Bach LA (2004) The insulin-like growth factor system: towards clinical applications. Clin Biochem Rev 25(3):155–164PubMedGoogle Scholar
  2. 2.
    Bonapace G, Concolino D, Formicola S, Strisciuglio P (2003) A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet 40:913–917. doi: 10.1136/jmg.40.12.913 CrossRefPubMedGoogle Scholar
  3. 3.
    Chernausek SD, Backeljauw PF, Frane J et al (2007) Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-1 deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 92:902–910. doi: 10.1210/jc.2006-1610 CrossRefPubMedGoogle Scholar
  4. 4.
    Laron Z (2004) Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958–2003. J Clin Endocrinol Metab 89:1031–1044. doi: 10.1210/jc.2003-031033 CrossRefPubMedGoogle Scholar
  5. 5.
    Laron Z (2008) Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity). Pediatr Endocrinol Rev 5:766–771PubMedGoogle Scholar
  6. 6.
    Laron Z, Lilos P, Klinger B (1993) Growth curves for Laron syndrome. Arch Dis Child 68:768–770. doi: 10.1136/adc.68.6.768 CrossRefPubMedGoogle Scholar
  7. 7.
    Laron Z, Roitman A, Kauli R (1979) Effect of human growth hormone therapy on head circumference in children with hypopituitarism. Clin Endocrinol (Oxf) 10(4):393–399. doi: 10.1111/j.1365-2265.1979.tb02094.x CrossRefGoogle Scholar
  8. 8.
    Walenkamp MJE, Karperien M, Pereira AM et al (2005) Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 90:2855–2864. doi: 10.1210/jc.2004-1254 CrossRefPubMedGoogle Scholar
  9. 9.
    Woods KA, Camacho-Hübner C, Bergman RN et al (2000) Effects of insulin-like growth factor I (IGF-1) therapy on body composition and insulin resistance in IGF-1 gene deletion. J Clin Endocrinol Metab 85:1407–1411. doi: 10.1210/jc.85.4.1407 CrossRefPubMedGoogle Scholar
  10. 10.
    Woods KA, Camacho-Hübner C, Savage MO, AJLl C (1996) Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 335:1363–1367. doi: 10.1056/NEJM199610313351805 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Daniela Concolino
    • 1
  • Gianluca Muzzi
    • 1
  • Simona Sestito
    • 1
  • Giovanna Vega
    • 1
  • Giuseppe Bonapace
    • 1
  • Pietro Strisciuglio
    • 1
  1. 1.Department of PediatricsUniversity “Magna Graecia” of CatanzaroCatanzaroItaly

Personalised recommendations